Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Group Study of A Lenalidomide (Revlimid«) Regimen or A Sequential Azacitidine (Vidaza«) plus Lenalidomide (Revlimid«) Regimen Versus Azacitidine (Vidaza«) Regimen for Therapy of Older Subjects with

 


A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Group Study of A Lenalidomide (Revlimid«) Regimen or A Sequential Azacitidine (Vidaza«) plus Lenalidomide (Revlimid«) Regimen Versus Azacitidine (Vidaza«) Regimen for Therapy of Older Subjects with


Trial Focus

Leukemia/Myelodysplasia

Objective

         This is a clinical trial of investigational drugs lenalidomide (Revlimid«) that will be administered by mouth and azacitidine (Vidaza«) which will be administered by injection.

IRB Protocol #

12-0145

Trial Status

Archived

Principle Investigator

DAN POLLYEA

Sponsor

Celgene Corporation

Contact

HEAGIE LEE at -- or HEA.LEE@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. The treatment period can last up to 48 months. The follow up period will consist of phone contact once a month for a minimum of 4 years. // Eligibility includes but is not limited to 65 years or older with acute myeloid leukemia (AML).Eligibility includes but is not limited to 65 years or older with acute myeloid leukemia (AML).